反应详情

(±)-(3-{(4-Methylbenzoyl)-[1-(4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4] triazin-2-yl)-propyl]amino}propyl)carbamic acid tert-butyl ester (Example 3 A, 42 mg, 0.09 mmol) was converted to the title compound (8 mg, 17%) in a manner similar to the preparation of (±)-{3-[{1-[3-(4-fluorobenzyl)-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl]-propyl}-(4-methylbenzoyl)-amino]-propyl}-carbamic acid tert-butyl ester, except that bromo-methylcyclopropane (15 mg, 0.11 mmol) was used instead of 4-fluorobenzyl bromide: 1H NMR (CDCl3) δ 7.40–7.22 (m, 5H), 7.04 (m, 1H), 6.57 (m, 1H), 6.00 (m, 1H), 4.41 (m, 1H), 3.81 (m, 1H), 3.65 (m, 1H), 3.40–3.05 (m, 3H), 2.69 (m, 2H), 2.38 (s, 3H), 2.27 (m, 1H), 1.97 (m, 1H), 1.61 (m, 2H), 1.39 (s, 9H), 1.27 (m, 2H), 0.80–1.10 (m, 3H), 0.59 (m, 2H).